FDA's complete response letter on Hospira Inc.'s biosimilar Retacrit shows the agency is not merely letting user fee goals under the 351(k) pathway pass it by.
Pfizer Inc., which completed its acquisition of Hospira in September, announced Oct. 27 that it received a complete response letter for Retracrit, a proposed biosimilar to epoetin alfa (